Use of cangrelor in percutaneous coronary interventions: a “new” weapon in the antithrombotic therapeutic armamentarium

• Published in: REC, Interventional cardiology (Internet. English ed.) Vol. 2; no. 4; pp. 244 - 246
• Main Authors: Luis Ferreiro, José, Gómez-Hospital, Joan Antoni
• Format: Journal Article
• Language: English
• Published: Permanyer 01.10.2020
• ISSN: 2604-7322; 2604-7322
• DOI: 10.24875/RECICE.M20000144

During the second half of 2019, cangrelor started selling in our country, a “new” antiplatelet drug with especial pharmacological properties that make it especially appealing for the management of certain clinical situations in the percutaneous coronary intervention (PCI) setting. The adjective “new” is in quotation marks because the clinical trial conducted proved its superiority compared to clopidogrel with ICP. The CHAMPION PHOENIX trial1 was published in 2013 and it was approved by regulatory authorities back in 2015. This delay has probably caused the scientific evidence to lose relevance and, in consequence this drug might not be widely accepted within the cardiology community. Also, the indication specified in the technical label is only based on the conditions of the clinical trial that prompted its approval—which is mandatory—not on real-world practices. This may be confusing when selecting those patients who may benefit from this drug.2 In short, cangrelor is an intravenous reversible, high-affinity antagonist of the platelet P2Y12 receptor of adenosine diphosphate to which it binds directly (without need for conversion into an active metabolite). In pharmacodynamic terms, the properties of cangrelor are: a) rapid onset of action (3 to 6 minutes); b) powerful dose-dependent effect (inhibition > 90% of the P2Y12 receptor...